Intensity Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw the re-election of two directors, approval of auditor ratification, and amendments to stock plans. All proposals passed by majority vote, and no questions were raised during the Q&A session.
Fiscal Year 2025
-
INT230-6, an intratumoral therapy combining SHAO, cisplatin, and vinblastine, showed high tumor retention, favorable safety, and promising efficacy in metastatic solid tumors, especially when ≥40% of tumor burden was injected. Median overall survival reached 12–19 months, with evidence of immune activation and abscopal effects.
-
Stockholders approved both a reverse stock split and an adjournment proposal, with the Board retaining discretion over the timing and ratio of the split. Final voting results will be disclosed in a Form 8-K. Forward-looking statements were noted as subject to risk factors.
-
The meeting confirmed a quorum, elected Dr. Mark A. Goldberg as Director through 2028, and ratified EisnerAmper LLP as auditors for 2025. No questions were raised by stockholders, and management highlighted standard forward-looking statement risks.
Fiscal Year 2024
-
The meeting saw the re-election of two directors, approval of the 2024 Employee Stock Purchase Plan, and ratification of the auditor. A quorum was present, and all proposals passed by majority vote. No questions were raised during the Q&A.